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1. Introduction
Menopause in breast cancer patients remains an issue
of clinical concern. The discontinuation of hormone-
replacement therapy (HRT) on diagnosis of breast
cancer is at present more emphasised with recent pub-
lications conﬁrming the detrimental eﬀect of HRT on
the breast [1,2]. Moreover, most non-hormonal inter-
ventions are of limited eﬃcacy or questionable safety [3–
8]. In the postmenopausal uterus, tamoxifen, the most
widely used endocrine treatment in the management of
breast cancer induces a wide range of uterine abnorm-
alities from hyperplasia, polyps, growth of ﬁbroids to
cancer [9–11]. Although most of these changes are be-
nign, many women undergo interventions to exclude
malignant disease.
Nowadays, third generation non-steroidal aromatase
inhibitors (NSAIs), such as anastrozole and letrozole,
and the steroidal aromatase inhibitor (SAI), exemestane,
are increasingly being used in the management of breast
cancer. All three aromatase inhibitors (AIs) have been
shown to be at least as eﬀective or superior to tamoxifen
in the metastatic setting [12–15], and are now challen-
ging tamoxifen in the adjuvant setting [16]. Prospective
studies primarily designed to compare the impact of
diﬀerent endocrine treatments on menopausal symp-
toms are limited. Similarly, although AIs are less likely
to induce uterine abnormalities compared with tamox-
ifen, little data are available. Our aim was to compare
the early eﬀects of tamoxifen and steroidal and NSAIs
on the occurence and severity of menopausal symptoms
in postmenopausal breast cancer patients. We also
aimed to compare early uterine sonographic changes
induced by these treatments.
2. Evaluation of early changes in menopausal symptoms
In a prospective single-centre study in 181 consecutive
postmenopausal breast cancer patients scheduled to
start endocrine treatment, a validated menopause
symptom questionnaire was completed by patients prior
to the start of endocrine treatment, and after 1 and 3
months of therapy [17].
Both ﬁrst-line treatments with either tamoxifen or
NSAIs resulted in a signiﬁcant increase in the occur-
rence and severity of hot ﬂashes (P < 0.0001 and
P = 0.014, respectively). Musculoskeletal pain sig-
niﬁcantly increased under NSAIs, (P = 0.0039), while
no signiﬁcant change occurred in patients receiving ﬁrst-
line tamoxifen (P = 0.33) and in those crossing-over
from tamoxifen to a steroidal or NSAI (P = 0.9225).
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Treatment was interrupted in four cases due to intoler-
ance; 2 on tamoxifen with intolerable hot ﬂashes and 2
on letrozole with severe joint and muscle pain.
3. Evaluation of early uterine changes
In 77 consecutive postmenopausal breast cancer pa-
tients scheduled to start endocrine treatment and who
provided written informed consent for uterine evalua-
tion, transvaginal ultrasonography (TVUS) was per-
formed before and after 3 months of therapy [18].
Tamoxifen signiﬁcantly increased double endometrial
thickness and uterine volume (P < 0.0001 and
P = 0.0062, respectively). Additionally, tamoxifen in-
duced internal cysts (40%), endometrial polyps (15%),
and increased the size of pre-existing ﬁbroids (25%). In
contrast, AIs did not stimulate endometrial growth and
were not associated with endometrial pathologies seen
under tamoxifen. Furthermore, AIs showed a trend to-
wards decreased endometrial thickness and uterine vo-
lume in patients previously exposed to tamoxifen
(P = 0.12).
4. Diﬀerences in side-eﬀects of tamoxifen and steroidal
and non-steroidal aromatase inhibitors?
There are some signiﬁcant diﬀerences between the
early eﬀects of tamoxifen and AIs on menopausal
symptoms and uterine changes of breast cancer patients.
Musculoskeletal pain occurring early in the treatment
with ﬁrst-line NSAIs may not only lead to possible
treatment interruptions, but may have long-term con-
sequences on themuscle and bone. In contrast, tamoxifen
has the advantage of preventing normal bone loss asso-
ciated with natural menopause [19]. In patients crossing-
over from tamoxifen to a steroidal or NSAI, tamoxifen
seems to blunt the eﬀect of AIs on joint and muscle pain
at least during the ﬁrst 3 months of therapy. The absence
of eﬀect on musculoskeletal symptom changes in this
subgroup may be due to either the short evaluation per-
iod, or the protective eﬀect of tamoxifen treatment, or
perhaps a possible bone-sparing eﬀect of the SAI ex-
emestane. Exemestane, being steroidal in structure, be-
longs to a diﬀerent category of AI. It is devoid of total
cross-resistance with NSAIs [20] and displays a diﬀerent
action (possibly androgen-mediated) on serum lipids
[21–23] and on bone [24]. However, whether the SAI
really has this advantage over NSAIs can only be de-
termined with certainty in larger studies with longer fol-
low-up or in adjuvant studies without the confounding
eﬀect of previous tamoxifen treatment.
In the postmenopausal uterus, tamoxifen and AIs
have a distinct eﬀect which can be documented as early
as 3 months after start of therapy with a relatively non-
invasive procedure such as TVUS. The atrophic eﬀects
of AIs on the uterus in contrast to the oestrogenic action
of tamoxifen are reassuring fromagynaecological pointof
view. Furthermore, an important ﬁnding is that AIs,
mostly exemestane in this series, may reverse tamoxifen-
associated uterine changes. Although it is interesting to
consider the possibility that a short treatment with AIs
in patients with tamoxifen-induced uterine abnormal-
ities could possibly reduce or obviate invasive proce-
dures such as hysteroscopy or curettage, the validity and
safety of such an approach warrants further evaluation.
Nevertheless, on the assumption that tamoxifen-induced
endometrial thickening by TVUS is often a precursor or
surrogate marker of endometrial pathologies [10], the
reversal of such suggests that tamoxifen therapy fol-
lowed by an AI may not only be more eﬀective as shown
in the recent MA-17 trial [25], but may, in the end, lead
to a reduction in the endometrial pathologies associated
with tamoxifen.
Diﬀerences in tolerability proﬁles between tamoxifen
and AIs and between the steroidal and non-steroidal
types are important. Whether the diﬀerence exists in
adverse side-eﬀects or in non-life-threatening side-eﬀects
which may reduce quality-of-life or aﬀect patient com-
pliance, these diﬀerences may be taken into account in
clinical decisions in the choice between diﬀerent drugs.
This is particularly true in cases where agents may have
minimal diﬀerences in eﬃcacy but exhibit marked
diﬀerences in tolerance. Issues on acute and long-term
side-eﬀects will also become more important in the
preventive setting, where otherwise healthy high-risk
women will be taking these drugs.
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